Erin Wright
Stock Analyst at Morgan Stanley
(4.58)
# 246
Out of 4,670 analysts
198
Total ratings
65.77%
Success rate
15.29%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Overweight | $119 → $127 | $121.84 | +4.24% | 7 | Nov 4, 2024 | |
| ALGN Align Technology | Maintains: Overweight | $310 → $280 | $225.89 | +23.95% | 20 | Oct 24, 2024 | |
| ELV Elevance Health | Maintains: Overweight | $643 → $551 | $402.55 | +36.88% | 2 | Oct 23, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: Underweight | $9 → $7 | $8.66 | -19.17% | 7 | Oct 11, 2024 | |
| ELAN Elanco Animal Health | Downgrades: Equal-Weight | $17 → $15 | $13.36 | +12.28% | 9 | Sep 19, 2024 | |
| HUM Humana | Initiates: Equal-Weight | $374 | $298.11 | +25.46% | 1 | Jun 24, 2024 | |
| PDCO Patterson Companies | Maintains: Equal-Weight | $35 → $28 | $20.46 | +36.85% | 6 | Jun 20, 2024 | |
| PETS PetMed Express | Maintains: Underweight | $6.5 → $3.5 | $4.78 | -26.78% | 11 | Jun 12, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $620 → $596 | $417.24 | +42.84% | 11 | May 14, 2024 | |
| NVST Envista Holdings | Downgrades: Equal-Weight | $33 → $21 | $21.48 | -2.23% | 6 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $522 → $548 | $623.19 | -12.07% | 4 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $382 → $392 | $328.45 | +19.35% | 3 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $18.75 | -4.00% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $75.08 | -13.43% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $23.74 | -32.60% | 20 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $39 | $18.77 | +107.78% | 11 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $58.01 | +72.38% | 4 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $590.87 | -0.65% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $248 | $176.96 | +40.14% | 5 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $239.67 | +25.17% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $142 | $163.59 | -13.20% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $20.78 | +102.12% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $235.84 | +22.12% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $195.77 | +79.80% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $5.22 | +742.91% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $337.75 | -46.41% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $90.52 | -81.22% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $34.89 | +246.80% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $513.26 | +13.00% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $10.36 | +237.84% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $214.25 | -4.32% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $17.87 | -38.44% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $201.82 | -22.21% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $22.84 | +66.37% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $12.35 | +37.65% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $542.22 | -43.20% | 1 | Oct 25, 2017 |
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $119 → $127
Current: $121.84
Upside: +4.24%
Align Technology
Oct 24, 2024
Maintains: Overweight
Price Target: $310 → $280
Current: $225.89
Upside: +23.95%
Elevance Health
Oct 23, 2024
Maintains: Overweight
Price Target: $643 → $551
Current: $402.55
Upside: +36.88%
Walgreens Boots Alliance
Oct 11, 2024
Maintains: Underweight
Price Target: $9 → $7
Current: $8.66
Upside: -19.17%
Elanco Animal Health
Sep 19, 2024
Downgrades: Equal-Weight
Price Target: $17 → $15
Current: $13.36
Upside: +12.28%
Humana
Jun 24, 2024
Initiates: Equal-Weight
Price Target: $374
Current: $298.11
Upside: +25.46%
Patterson Companies
Jun 20, 2024
Maintains: Equal-Weight
Price Target: $35 → $28
Current: $20.46
Upside: +36.85%
PetMed Express
Jun 12, 2024
Maintains: Underweight
Price Target: $6.5 → $3.5
Current: $4.78
Upside: -26.78%
IDEXX Laboratories
May 14, 2024
Maintains: Overweight
Price Target: $620 → $596
Current: $417.24
Upside: +42.84%
Envista Holdings
Apr 26, 2024
Downgrades: Equal-Weight
Price Target: $33 → $21
Current: $21.48
Upside: -2.23%
Apr 15, 2024
Maintains: Overweight
Price Target: $522 → $548
Current: $623.19
Upside: -12.07%
Mar 4, 2024
Reiterates: Overweight
Price Target: $382 → $392
Current: $328.45
Upside: +19.35%
Feb 20, 2024
Initiates: Overweight
Price Target: $18
Current: $18.75
Upside: -4.00%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $75.08
Upside: -13.43%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $23.74
Upside: -32.60%
Nov 3, 2023
Maintains: Overweight
Price Target: $43 → $39
Current: $18.77
Upside: +107.78%
Nov 2, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $58.01
Upside: +72.38%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $590.87
Upside: -0.65%
Nov 15, 2022
Maintains: Overweight
Price Target: $264 → $248
Current: $176.96
Upside: +40.14%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $239.67
Upside: +25.17%
Aug 22, 2022
Assumes: Equal-Weight
Price Target: $142
Current: $163.59
Upside: -13.20%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $20.78
Upside: +102.12%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $235.84
Upside: +22.12%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $195.77
Upside: +79.80%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $5.22
Upside: +742.91%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $337.75
Upside: -46.41%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $90.52
Upside: -81.22%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $34.89
Upside: +246.80%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $513.26
Upside: +13.00%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $10.36
Upside: +237.84%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $214.25
Upside: -4.32%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $17.87
Upside: -38.44%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $201.82
Upside: -22.21%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $22.84
Upside: +66.37%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $12.35
Upside: +37.65%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $542.22
Upside: -43.20%